Mumbai-headquartered Bharat Serums and Vaccines Limited (BSV) hosted the groundbreaking ceremony of its new manufacturing plant at Genome Valley in Hyderabad, Telengana. The company is owned by Advent, an American private equity fund.
Spread across 10 acres, the $22 million manufacturing facility will increase the company’s capacity to produce injectables with the commissioning of the fill-finish formulation line in Phase I, and an additional multi-product line in Phase II of the project.
The company currently has a manufacturing facility in Ambernath, Maharashtra, that caters to domestic and more than 80 export markets. It also has a manufacturing facility in Aachen, Germany, that serves the international markets.
BSV is amongst the top 10 biotech companies in India and has a portfolio of over 145 brands. It plans to produce women’s health products, anti-rabies vaccines, immunoglobulins and hormones, among others products.
